AZN

Astrazeneca Plc

• NASDAQ·18h ago

  AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

• Dow Jones·1d ago

  AstraZeneca's Drug Combination for Prostate Cancer Treatment Gets U.S. Approval

• PUBT·1d ago

  AstraZeneca says FDA approves Truqap combo for PTEN-deficient metastatic hormone-sensitive prostate cancer

• Reuters·1d ago

  BRIEF-Astrazeneca Says Truqap Combination Approved In US For A Type Of Prostate Cancer

• Reuters·1d ago

  ASTRAZENECA: TRUQAP COMBINATION APPROVED IN US AS FIRST AND ONLY TARGETED TREATMENT FOR PTEN-DEFICIENT METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

• NASDAQ·2d ago

  Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

• Reuters·2d ago

  Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

• PUBT·3d ago

  Hansa Biopharma appoints Fredrik Röök as VP business development

• Benzinga·4d ago

  AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

• Reuters·4d ago

  UK Stocks-Factors to watch on June 9

• Reuters·4d ago

  PRESS DIGEST-Financial Times - June 9

• PUBT·4d ago

  AstraZeneca publishes investor presentation on elecoglipron Phase II data in obesity and type 2 diabetes

• Benzinga·5d ago

  'AstraZeneca's Obesity Pill Matches Rivals In Phase 2, Anchoring $5B Franchise Push; AstraZeneca Obesity Pill Helps Patients Lose 10.5% Of Body Weight In Trial' - Endpoints News

• PUBT·5d ago

  AstraZeneca advances oral GLP-1 elecoglipron to Phase III after 11.8% weight loss in VISTA trial

• Reuters·5d ago

  AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial